TA, you are going to have to do better than using truth to tell lies; precisely what people engaged in disinformation/short & distort campaigns do. You claim that Sintx is a share dilution scam because Sintx has to raise funds to continue operations. That is not a share dilution scam per your reference. What has happened here is due to the short and distort campaign taking advantage of the fact that Sintx needs to raise money to fund R&D; which leads to it overly diluting with each offering and then reverse spliting to stay listed. Is my description of what has occurred the last 9 years accurate or yours? First off, for Sintx to be a share dilution scam it would need to raise funds just because. There is little detail on this sort of scam so im going to go out on a limb and assume there is not much of real value being created on the company side that is involved in these sorts of scam.
Why Sintx/SINT cannot be a share diluting scam!
During Sonny's tenure as CEO, Sintx IP has grown significantly, something you cannot honestly deny. Meaning Sonny has overseen, partially created as well as hes a contributing scientist, a massive expansion of Sintx product candidates branching off into many new possible markets. From Cancer to Anti-pathogenic to Aerospace/Defense to many other possible uses just within the ortho/medical sector. So no Sintx cannot be a share dilution scam for the simple reason so much value has been created but for reasons i already shown, that value is not reflected by the markets because Sintx has been under a short and distort campaign for 9 years as i show in links below. Sintx market value should exceed $230m. So why is it currently worth $3.5m? I dont just claim this, anyone can verify that a comparable materials company was acquired for 230m by Zimmer back in 2003. As Sintx material is superior to that of Implex Hydrocel, has more strategic partnerships in place with at least 2 large companies, & can be used in so many additional markets in addition to the ortho market, its worth more than $230m. In fact Joev2 still hasnt answered my question if Sintx IP is worth more than 1 billion based on its addressable markets and known/suspected strategic partners.
In conclusion, Sintx/Amedica, cannot be share dilution scam for the simple reason that too much value been created with the funds raised. Instead evidence suggests SINT only APPEARS to be a share dilution scam because of the conspiracy of hedge funds engaged in a short & distort campaign against it for 9 years.
This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544
I go into some of the evidence of this in the February 2023 offering where they drove the price up & naked shorted it down. Ansons family of funds participated in every offering in 2023 up to the recent RS. Anson and the other funds its associated with are known for their short and distort actvity and are under investigation by the DOJ. SEC slapped it with a ticket fine basically that will in no way discourage its shorting and distorting methods. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602472
========================================
The Value being created at Sintx can be seen in the following posts and links:
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies